Please Login


Cancel
Become a Member | Why Join?
  • I am an Individual
    • I Work in Industry
    • I Work in Healthcare
    • I Work in Education

Anaphylaxis Campaign

Supporting people at risk of severe allergies

DonateEMERGENCY INSTRUCTIONS

  • Who We Are
    • Our Team
    • Our Ambassadors
    • Vacancies
  • Media Centre
    • Latest News
    • Press Releases
    • Your Stories
    • Facts and Figures
  • Contact Us
    • Anaphylaxis Campaign’s Helpline
    • Helpline FAQs
    • Keep In Touch
    • Share Your Story
  • 0 items£0.00
  • Home
  • What is Anaphylaxis
    • 14 Major Allergens
    • Signs and Symptoms
    • Glossary Of Terms
  • Living with Anaphylaxis
    • Care and Medication
    • Infant Weaning Guidance
    • Guidance for Young Adults
      • Managing Allergens at University
      • Easy to ASK Campaign
      • #TakeTheKit
    • Shopping and Preparing Food
    • A Guide to Eating Out
    • Travelling
      • Booking your Flight
      • The Day of your Flight
      • Preparing to Travel
      • When Abroad
      • Airline Allergy Policies
      • Translation Cards
      • Travel Insurance
      • Allergy Organisations Abroad
    • Seasonal Events
      • Valentine’s Day
      • Mother’s Day
      • Easter
      • Father’s Day
      • Summer Festivals
      • Halloween
      • Diwali
      • Christmas
    • Living with Natural Rubber (NRL) Allergy
      • Latex Allergy and The Law
      • Latex Allergy Forum
      • NRL and the Workplace
    • The NHS
  • Support Us
    • Donate
      • Make a One-Off Donation
      • Make a Regular Donation
      • Gift Aid your Donations
      • Give as you Shop
      • Give through your Salary
      • Give in Memory
      • Leave a Gift in your Will
    • Fundraising
      • Fundraising Hall of Fame
      • Register your Fundraising Plans
      • Find an Event
      • Awareness and Fundraising in Schools
    • Membership
    • Volunteer
      • Allergy Buddy
      • Community Volunteer
      • Media Volunteers
      • Volunteer as a Lay Reviewer
      • Volunteer at our Head Office
  • Events
    • Join us at the Allergy & Free From Show, 1-3 July
    • Upcoming Webinars
  • Information & Training
    • Anaphylaxis Training
      • Allergywise Training Courses
      • For Parents and Carers of Severely Allergic Children
      • For Adults with Severe Allergies
      • For Schools
      • For Families and Carers of Pre-School Children
      • For Pharmacists
      • For Healthcare Professionals
      • For GPs and Practice Nurses
      • For Careworkers
      • For Hospital Ward Staff
    • Factsheets
    • Knowledgebase
    • Our Webinars
    • Allergy Alerts
    • Support Groups
    • Our Posters
    • Useful Links
    • Facts and Figures
    • Research
  • Campaigning
    • Making Schools Safer Project
      • Spare Pens in Schools
    • Guidance for Young Adults
      • Managing Allergens at University
    • Managing Allergens in the Workplace
  • COVID-19 advice
    • Covid-19 Vaccines and Allergies
    • COVID-19 FAQs
  • Shop

Promising results as Viaskin Peanut trial in peanut-allergic toddlers concludes

14th June 2022 by Claire Thompson

A recent trial by DBV Technologies has produced promising results for very young children with peanut allergies and their families.

The trial assessed whether Viaskin Peanut – an immunotherapy skin patch – was safe, and if it worked for children between one and three years old. Most peanut-allergic children are diagnosed between these ages, but there are currently no approved therapies for this age group.

For a successful result, toddlers intolerant to tiny amounts (10 mg or less) of peanut protein, needed to be able to tolerate 300 mg or more after 12 months. Toddlers who could already manage more than 10 mg had to be tolerant of 1,000 mg of peanut protein after 12 months.

Results:

  • Did it work? Viaskin Peanut met the trial’s criteria for 67% of toddlers on the trial, compared to 33.5% in a placebo trial.
  • Was it safe? 8.6% of toddlers had adverse reactions – this was most commonly mild to moderate skin reactions – compared to 2.5% in the placebo trial.

The findings matched results from other trials DBV Technologies has carried out with children aged four and over. Many of the families (88%) have opted for the toddlers to continue to benefit from the treatment by signing up for a further long-term trial.

Simon Williams, Chief Executive of the Anaphylaxis Campaign, says, “It’s easy for parents of small children to get disheartened about peanut allergy when there is such a lack of treatments. But the truth is, research and development is evolving all the time. This latest trial from DBV Technologies gives us further hope for a much brighter future for families living with peanut allergy.”

Dr Pharis Mohideen, Chief Medical Officer of DBV Technologies, said, “We are thrilled by the topline results of EPITOPE, our second Phase 3 clinical trial to evaluate the safety and efficacy of Viaskin Peanut.

“We are grateful to the toddlers and their parents, caregivers and allergists who are contributing to a brighter future by having participated in this first-of-its kind trial.”

Filed Under: News, Uncategorised Tagged With: allergens, allergic reactions, DBV Technologies, food allergies, immunotherapy, peanut allergy, peanuts, reaction, research, severe allergies, Viaskin

DBV Technologies announces filing and validation of marketing authorization application for Viaskin™ Peanut by European Medicines Agency

17th November 2020 by anaphylaxis

DBV Technologies, a biopharmaceutical company and Corporate Member of the Campaign, announced on November 5 that its product Viaskin™ Peanut (DBV712) has been validated by the European Medicines Agency (EMA). The validation confirms that the submission is sufficiently complete to begin the formal review process for the investigational non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.

To read the full press release, please go here

Filed Under: News Tagged With: DBV Technologies, Viaskin

Head Office

1 Alexandra Road
Farnborough
Hampshire
GU14 6BU

General Enquiries

  • +44 (0) 1252 546100
  • admin@anaphylaxis.org.uk

Helpline

  • +44 (0) 1252 542029
  • info@anaphylaxis.org.uk

Press Office

  • +44 (0) 7393 234092
  • press@anaphylaxis.org.uk

Fundraising

  • +44 (0) 1252 893850
  • fundraising@anaphylaxis.org.uk

Get Social

  • © Anaphylaxis Campaign 2022
  • Terms & Conditions |
  • Privacy & Cookies Policy |
  • Fundraising Policy |
  • Feedback Policy |
  • Complaints Procedure

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group), a charity registered in England and Wales (1085527) and a registered company limited by guarantee in England and Wales (04133242).
Registered in Scotland - charity number: SC051390.
Our registered company address is Anaphylaxis Campaign, 1 Alexandra Road, Farnborough, GU14 6BU.